DICE Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
90
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.43B
DICE Therapeutics General Information
Description
Developer of innovative medicines in immunology designed to assist patients with debilitating diseases. The company specializes in building a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas and develops oral therapeutics against well-validated targets in immunology, aiming to achieve comparable potency to systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas.
Contact Information
Website
www.dicetherapeutics.comCorporate Office
- 400 East Jamie Court
- Suite 300
- South San Francisco, CA 94080
- United States
Corporate Office
- 400 East Jamie Court
- Suite 300
- South San Francisco, CA 94080
- United States
DICE Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 09-Aug-2023 | $2.43B | Completed | Generating Revenue | ||
| 8. IPO | 15-Sep-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C1) | 21-Aug-2021 | Completed | Pre-Clinical Trials | |||
| 6. Debt - General | 13-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series C) | 08-Jan-2021 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series B) | 11-Jul-2018 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC | 16-Mar-2016 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC | 18-Jun-2015 | $4M | $7.5M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC | 01-Jan-2014 | $3.5M | $3.5M | Completed | Pre-Clinical Trials |
DICE Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series S-1 |
DICE Therapeutics Comparisons
Industry
Financing
Details
DICE Therapeutics Competitors (166)
One of DICE Therapeutics’s 166 competitors is Protagonist Therapeutics, a Formerly VC-backed company based in Newark, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics | Formerly VC-backed | Newark, CA | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Damora Therapeutics ( Drug Discovery) | Formerly VC-backed | Waltham, MA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Abeona Therapeutics | Corporation | Cleveland, OH |
DICE Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
DICE Therapeutics Patents
DICE Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213589-A1 | Pyrazolopyrimidine compounds as tnfa modulators | Pending | 03-Apr-2025 | ||
| EP-4808657-A1 | Alpha 4 beta 7 integrin modulators and uses thereof | Pending | 15-Nov-2023 | ||
| EP-4808917-A1 | Alpha 4 beta 7 integrin modulators and uses thereof | Pending | 15-Nov-2023 | ||
| WO-2025106410-A1 | Alpha 4 beta 7 integrin modulators and uses thereof | Inactive | 15-Nov-2023 | ||
| WO-2025106843-A1 | Alpha 4 beta 7 integrin modulators and uses thereof | Inactive | 15-Nov-2023 | A61P37/02 |
DICE Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
DICE Therapeutics Former Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Access Biotechnology | Corporate Venture Capital | Minority | ||
| Agent Capital | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Altitude Life Science Ventures | Venture Capital | Minority | ||
| Asymmetry Capital Management | Hedge Fund | Minority |
DICE Therapeutics ESG
Risk Overview
Risk Rating
Updated June, 30, 2023
27.14 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
DICE Therapeutics FAQs
-
When was DICE Therapeutics founded?
DICE Therapeutics was founded in 2013.
-
Where is DICE Therapeutics headquartered?
DICE Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of DICE Therapeutics?
DICE Therapeutics has 90 total employees.
-
What industry is DICE Therapeutics in?
DICE Therapeutics’s primary industry is Drug Discovery.
-
Is DICE Therapeutics a private or public company?
DICE Therapeutics is a Private company.
-
What is the current valuation of DICE Therapeutics?
The current valuation of DICE Therapeutics is .
-
What is DICE Therapeutics’s current revenue?
The current revenue for DICE Therapeutics is .
-
How much funding has DICE Therapeutics raised over time?
DICE Therapeutics has raised $452M.
-
Who are DICE Therapeutics’s investors?
Access Biotechnology, Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, and Asymmetry Capital Management are 5 of 20 investors who have invested in DICE Therapeutics.
-
Who are DICE Therapeutics’s competitors?
Protagonist Therapeutics, NGM Biopharmaceuticals, Damora Therapeutics ( Drug Discovery), Genentech, and Abeona Therapeutics are some of the 166 competitors of DICE Therapeutics.
-
When was DICE Therapeutics acquired?
DICE Therapeutics was acquired on 09-Aug-2023.
-
Who acquired DICE Therapeutics?
DICE Therapeutics was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
